## Acute Dyspnea

David Jimenez, MD, PhD





#### **Disclosures for Dr. Jimenez**

Research Support	Daiichi Sankyo, Sanofi	
Employee	No relevant conflicts of interest to declare	
Consultant and/or Honoraria	Bayer, Boehringer Ingelheim, BMS, Daiichi Sankyo, Leo Pharma, Pfizer, ROVI, Sanofi	
Stockholder	No relevant conflicts of interest to declare	
Speakers Bureau	Bayer, BMS, Sanofi	
Scientific Advisory Board	See consultant	



# **Case presentation**

- 52 year-old man; morbidly obese (BMI: 40 kg/m<sup>2</sup>)
- Presented at ED: increasing dyspnoea over 6 weeks, now almost at rest; substernal chest discomfort
- OSA on CPAP treatment (compliant)
- COPD: ratio of forced expiratory volume in 1 second (FEV<sub>1</sub>) to forced vital capacity (FVC), 0.59; FEV<sub>1</sub>, 64% of the predicted value. No previous admissions because of AECOPD
- No hypertension. No history of CAD
- History of unprovoked intermediate-risk PE four months ago; on warfarin therapy



## **Case presentation**

**Clinical findings at presentation:** 

- BP: 110/70 mmHg; HR: 116/min; resp. rate: 28/min; SO<sub>2</sub>: 88% on room air, increasing to 96% with supplemental oxygen (2 liters)
- Heart examination: no murmurs
- Lung examination: breath sounds disminished
- Jugular venous distention difficult to assess (due to obesity)
- Chronic venous insufficiency of lower extremities present




#### Laboratory

- Normal blood count
- Creatinine: 0,9 mg/dl
- GPT: 56 U/L; GOT: 123 U/L
- hsTnT: 0 pg/mL; BNP: 180 pg/mL
- INR: 2.7

#### **Blood gas analysis**

• pH: 7.45; PaCO<sub>2</sub>: 32 mm Hg; PaO<sub>2</sub>: 55 mm Hg; lactate normal











# Qu. 1 Which is the most likely diagnosis? MCQ

- **1.COPD** exacerbation
- 2. Congestive heart failure
- 3.Recurrent PE
- 4. Pulmonary hypertension
- 5.Panic attack




## **Respiratory physician**

### **Does this patient have a COPD exacerbation?**



## **Disease severity and exacerbations**




**Figure 1.** Association of Disease Severity with the Frequency and Severity of Exacerbations during the First Year of Follow-up in Patients with Chronic Obstructive Pulmonary Disease.

Patients with two or more exacerbations during the year were considered to have frequent exacerbations. An exacerbation requiring hospitalization was classified as severe. Disease severity was classified according to the stages of disease defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD). P<0.001 for both comparisons.



#### Hurst JR, N Engl J Med 2010

# **History of exacerbations**





Hurst JR, N Engl J Med 2010

# **Respiratory physician**

#### **Does this patient have COPD exacerbation?**

- No cough or sputum purulence
- Mild COPD
- No history of exacerbations
- Discrepancy between COPD stage and pulmonary arterial enlargement on chest X-ray





#### **Does this patient have recurrent PE?**



## **Prevalence of PE in COPD exacerbations**





FIGURE 2. The prevalence of PE across different sites. The filled circles represent the mean, and the line bars represent SE; p value for overall = 0.014; p value for emergency department (ER) is not calculable because there was only one study; p value for studies that evaluated inpatients and outpatients = 0.133; p value for studies that evaluated only hospitalized patients = 0.034.



Rizkallah J, Chest 2009

# **Risk of venous thromboembolism recurrence**

#### Metaanalysis including 15 trials, 27,237 patients





#### Limone BL, Thromb Res 2013

## **Risk factors for VTE recurrence**

#### Early recurrence<sup>1</sup>

- Poor quality of anticoagulation (failure to achieve therapeutic aPTT and INR)
- Cancer

19

aPTT, activated partial thromboplastin time: BMI. bodv mass index: INR. international normalized ratio.





# **Diagnosis of recurrent PE: REPEAD study**


**516 patients with suspected recurrent PE** 

Pathway	Ν	3-month VTE risk % (95% CI)
PE unlikely, normal DD	88	0
PE unlikely, abnormal DD <i>or</i> PE likely, negative CTPA	249	2.8 (1.2-5.5)



Mos IC, Thromb Res 2014

# **Case: CT pulmonary angiography**







## **Does this patient have pulmonary hypertension?**



**Does this patient have pulmonary hypertension?** 


- COPD and pulmonary hypertension (3.1)
- OSA and pulmonary hypertension (3.4)
- Chronic thromboembolic pulmonary hypertension (4.1)



## **Heart Team**

#### Does this patient have COPD pulmonary hypertension?

- Few epidemiological data (most in very severe COPD)
- Prevalence in patients listed for lung transplantation: 31%






#### Cuttica MJ, Respir Med 2010

## **Heart Team**

#### **Does this patient have COPD pulmonary hypertension?**

 Pulmonary hypertension increases mortality in advanced COPD





Cuttica MJ, Respir Med 2010




#### **Does this patient have COPD pulmonary hypertension?**

• Discrepancy between COPD stage and pulmonary arterial enlargement on chest X-ray



### **Heart Team**

#### **Does this patient have OSA pulmonary hypertension?**






#### Vitarelli A, Can J Cardiol 2015



# Does this patient have chronic thromboembolic pulmonary hypertension?




# **Natural history of CTEPH**





# **Natural history of CTEPH**






# Qu. 2 Regarding CTEPH, which of the following is true?

- 1.The prevalence of CTEPH after PE is 15% after 2 years2.Multiple episodes of PE increase the risk of CTEPH3.A normal V/Q scan does not exclude the disease4.The treatment of choice for CTEPH is balloon angioplasty
- 5. The treatment of choice for CTEPH is epoprostenol



# **Diagnostic pathway for suspected CTEPH**






www.escardio.org


#### Konstantinides S, Eur Heart J 2015


# **Case: echocardiography**





# Case: V/Q scan










Q scan

# **Case: Pulmonary angiogram**





Right



#### Hemodynamic data on right heart catheterization

- •RAP: 26 mmHg
- •PAP: 90/35 mmHg (mean, 57 mmHg)
- •PAWP: 16 mmHg
- •Cardiac output: 2.5 L/min
- PVR: 1294 dyn·sec/cm<sup>5</sup>
- Pulmonary artery saturation: 43%






**Final diagnosis** 

Chronic thromboembolic pulmonary hypertension Chronic obstructive pulmonary disease (mild) Obstructive sleep apnea





BPA, balloon pulmonary angioplasty.

#### Galie N, Eur Heart J 2016

Acute dyspnea is a complex symptom

Different clinical situations (often combined) may cause acute dyspnea

A multidisciplinary approach to patients with acute dyspnea might improve patient outcomes



# Thank you!



